USA flag logo/image

An Official Website of the United States Government

A novel ellipticine analog as a therapeutic candidate for acute myeloid leukemia

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93602
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA141915
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CLEVELAND LEUKEMIA THERAPEUTICS, LLC
11000 CEDAR AVE CLEVELAND, OH 44106-3069
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: A novel ellipticine analog as a therapeutic candidate for acute myeloid leukemia
Agency: HHS
Contract: 1R43CA141915-01
Award Amount: $153,770.00
 

Abstract:

DESCRIPTION (provided by applicant): Existing therapeutic agents for Acute Myeloid Leukemia (AML) are inadequate to due poor efficacy and severe side effects. This is especially a problem in adults where the 5 year survival is less than 20-50%. Differentai tion therapy for AML holds significant promise in leading to more efficacious and less toxic therapies. AML is a disease characterized by the arrest of differentiation of immature myeloid cells. After leukemic cells undergo terminal differentiation, they l ose their ability to proliferate. The potential of differentiation therapy has been demonstrated by the use of the differentiation agent, ATRA, for one relatively uncommon subset of AML, acute promyelocytic leukemia. With the use of ATRA 75-85% of acute pr omyelocytic leukemia patients can now be cured. We have recently identified a novel differentiation-inducing agent, CLT731, that exhibits potent in vitro leukemia differentiation-inducing activity and preliminary evidence of mouse in vivo activity. CLT731 is an analogue of ellipticine, an agent that has perviously been found to have anti-tumor activity but also exhibits high toxicity. As CLT731 has preferential activity on leukemic cells, it appears to have a significantly reduced toxicity profile. The aims of this phase I project are to 1) demonstrate the promise of a CLT731 in mouse AML model systems 2) demonstrate the activity of this compound on patient samples in vitro and 3) to assess its potential toxicities. Due to the enormous need for novel AML the rapeutics, especially agents with reduced toxicity, this work has the potential to improve the quality of life for patients with AML. PUBLIC HEALTH RELEVANCE: This project is highly relevant to public health as its main objective is to develop a novel the rapy for patients with Acute Myeloid Leukemia that is both efficacious and has low toxicity. As the current AML therapeutics have low efficacy and high toxicities, there is a significant need for new therapies for AML.

Principal Investigator:

Mukesh K. Agarwal
AGARWAMUKESH@YAHOO.COM

Business Contact:

Mukesh Agarwal
Small Business Information at Submission:

CLEVELAND LEUKEMIA THERAPEUTICS, LLC
CLEVELAND LEUKEMIA THERAPEUTICS, LLC 11000 CEDAR AVE, STE 146B CLEVELAND, OH 44106

EIN/Tax ID: 126292798
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No